Analysis for Virus-neutralizing antibodies
NewsIn June 2020, scientists from the University of North Carolina (USA) developed a test for the detection of antibodies to the receptor-binding domain (RBD) of the surface glycoprotein S (spike) of the SARS-CoV-2 coronavirus.
- It allows you to assess the presence of immunity to a new coronavirus infection
The receptor-binding domain (RBD) is a special protein structure that is specific to the SARS — CoV-2 virus and is located on the "crown spikes".
With the help of RBD, the virus binds to the receptor of a human cell and penetrates it.
At the same time, the human immune system detects the receptor-binding domains of the virus and produces anti-RBD antibodies in response, blocking them, and thus preventing the virus from entering the cells.
- Thus, anti-RBD antibodies are virus-neutralizing antibodies.
RBD is absent in other known coronaviruses, so antibodies to this domain are highly specific to SARS-CoV-2.
The determination of antibodies to RBD is used for:
- verification of positive results for SARS-CoV-2 antibodies;
- determination of protective antibodies against SARS-CoV-2 in patients who have been ill;
- selection of plasma donors used for the treatment of severe patients with coronavirus infection;
- determination of protective antibodies in vaccinated patients.
In the Center for Personalized Medicine of the MCSC, you can be tested for the detection of IgG immunoglobulins to the receptor-binding domain (RBD) of the surface glycoprotein S (spike).
Our phone number: 8 (495) 305-05-50
